SCHEMBL2360469

SCHEMBL2360469

COc1ccc(N2CCN(c3ccc(OC)c(N4CCN(C)CC4)n3)C2=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 6/20 0.45
ALDH1A1 P00352 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
CLK4 Q9HAZ1 1/20 0.41
POLB P06746 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
RAD52 P43351 1/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
TRPV4 Q9HBA0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2333076 0.90 HRH4 (0.42) HRH4ALDH1A1KMT2ASMN1; SMN2MAPT
SCHEMBL2328041 0.90 HTR2A (0.44) HRH4ALDH1A1CYP1A2CYP2C19KMT2A
SCHEMBL14733339 0.89 HRH4 (0.45) HRH4ALDH1A1CYP1A2CYP2C19CLK4
SCHEMBL12445260 0.82 MAPT (0.45) HRH4ALDH1A1CYP1A2CYP2C19CLK4
SCHEMBL2331617 0.79 HRH4 (0.44) HRH4ALDH1A1CYP1A2CYP2C19CLK4
SCHEMBL2359748 0.78 HRH4 (0.43) HRH4ALDH1A1CYP1A2CYP2C19CLK4
SCHEMBL14733340 0.74 DRD2 (0.43) HRH4ALDH1A1KMT2AMAPTNPC1
SCHEMBL14733341 0.74 KMT2A (0.47) HRH4ALDH1A1CYP1A2KMT2AMAPT
SCHEMBL2360158 0.72 HRH4 (0.44) HRH4ALDH1A1POLBSMN1; SMN2MAPT
SCHEMBL2360090 0.71 CYP1A2 (0.43) HRH4ALDH1A1CYP1A2CYP2C19CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US claimed
EP-2536711-A1 5-HT RECEPTOR MODULATORS Cambridge Enterprise Limited (GB) 2012-12-26 EP claimed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO claimed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
US-20130053372-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED 2013-02-28 US disclosed
WO-2011098776-A1 5-HT RECEPTOR MODULATORS CAMBRIDGE ENTERPRISE LIMITED (GB) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053372-A1 5-HT RECEPTOR MODULATORS HTR1B, HTR5A, HTR1A HRH4 350/4885ALDH1A1 987/4885CYP1A2 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.